Why the study?
Does aprindine suppress ventricular arrhythmias in canine models and what are the minimum effective plasma concentrations?
Does aprindine suppress ventricular arrhythmias in canine models and what are the minimum effective plasma concentrations?
Aprindine effectively suppresses various canine ventricular arrhythmias, though the required plasma concentration varies by arrhythmia etiology and individual sensitivity.
Aprindine efficacy in canine models warrants caution against human use; leaves open pharmacokinetic-guided clinical trials.
Antiarrhythmic effects of aprindine were examined using three canine ventricular arrhythmia models (induced by digitalis, adrenaline, and two-stage coronary ligation), and the minimum effective plasma concentration of aprindine was determined for each arrhythmia model. Aprindine suppressed all three arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by digitalis, adrenaline, and 24-h and 48-h coronary ligation were 0.8 +/- 0.4, 1.0 +/- 0.4, 1.6 +/- 0.3, and 3.1 +/- 0.5 micrograms/ml, respectively (mean +/- SD, n = 6-7). The minimum effective plasma concentrations of aprindine for digitalis- and adrenaline-induced arrhythmias were significantly lower than those for coronary ligation-induced arrhythmias. Oral aprindine was also effective in suppressing both the 24- and 48-h coronary ligation-induced arrhythmias. Aprindine had a hypotensive effect when it was given intravenously, but this effect was not observed when it was given orally. The correlations between the aprindine plasma concentrations and the antiarrhythmic effects were not very strong and indicated individual variations in sensitivity to aprindine.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: